Knowledge Distillery

Case fatality rates (CFR) of the novel 2019 coronavirus disease (COVID-19) have been reported ranging between 0% to 40% among Parkinson’s disease (PD)…

The COVID-19 pandemic has impacted the delivery of care to people with epilepsy (PWE) in multiple ways including limitations on in-person contact and…

The objective of this study was to evaluate patient perspectives regarding the use of natalizumab and anti-CD20 therapies (rituximab and ocrelizumab)…

The objective of this study, recently published in Journal of Parkinson’s Disease, was to rapidly identify areas of need to help improve care in…

In this article the authors systematically reviewed the literature on COVID-19 in patients with multiple sclerosis (MS). They searched PubMed, Scopus,…

Parkinson’s disease (PD), possibly due to associated factors. This study aimed to systematically review the factors associated with COVID-19 in people…

This study assessed the prevalence and risk factors for SARS-CoV-2 infection in patients with epilepsy (PWE). Additionally, the course of COVID-19 and…

Parkinson’s Disease (PD) is among one of the common comorbidities in older patients. People with PD may be more vulnerable to severe pneumonia, due to…

Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of Coronavirus 2019 (COVID-19) mainly due to respiratory muscle…

The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an opportunistic pathogen that infects the upper respiratory tract in humans and…

The effects of the COVID‐19 pandemic on telemedical care have not been described on a national level. Thus, the authors investigated the medical…